Kura Oncology
KURA
171 hedge funds and large institutions have $1.4B invested in Kura Oncology in 2021 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 66 increasing their positions, 50 reducing their positions, and 20 closing their positions.
110% more call options, than puts
Call options by funds: $4.73M | Put options by funds: $2.25M
32% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 50
5% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 20
0% more funds holding
Funds holding: 171 → 171 (0)
1.55% less ownership
Funds ownership: 103.59% → 102.04% (-1.6%)
28% less capital invested
Capital invested by funds: $1.94B → $1.4B (-$542M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$44.5M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$23M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$10.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$39.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$34.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$34.1M |
| 4 |
RI
RTW Investments
New York
|
-$30.6M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$22.7M |
KURA Hedge Fund Activity: Q2 2021 in Review
171 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q2 2021, worth a combined $1.4B — down 28% from $1.94B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new KURA positions and 20 closed out — a net gain of 1 holder — while 66 added to existing stakes and 50 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $44.5M. The largest seller was Victory Capital Management, cutting an estimated $39.7M.
- 171 institutional investors held Kura Oncology (KURA) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $1.4B of Kura Oncology stock for Q2 2021, down 28% quarter-over-quarter.
- 21 funds opened new Kura Oncology positions in Q2 2021 and 20 closed out, a net change of +1 holder.
- The largest Kura Oncology buyer in Q2 2021 was Deerfield Management, an estimated $44.5M added.
- The largest Kura Oncology seller in Q2 2021 was Victory Capital Management, an estimated $39.7M sold.
Based on aggregated 13F filings for Q2 2021.